Pasireotide s.c. in patients with Post-Bariatric Hypoglycaemia

• Research type

  Research Study

• Full title

  A double-blind randomized placebo-controlled dose-finding phase II study to assess the efficacy and safety of pasireotide s.c. in patients with Post-Bariatric Hypoglycaemia

• IRAS ID

  1008341

• Contact name

  Raffaele Sabia

• Contact email

  sabia.r@recordati.it

• Sponsor organisation

  Recordati AG

• Clinicaltrials.gov Identifier

  NCT05928390

• Research summary

  Phase II clinical study designed to find the best s.c. (subcutaneous, i.e. under the skin) Pasireotide dose to treat patients who have had a Bariatric surgery and Hypoglycaemia (low glucose levels), where neither the patient nor the doctor knows if active medicine or placebo (looks like a medicine but contains no active ingredient) is administered

• REC name

  North West - Greater Manchester South Research Ethics Committee

• REC reference

  24/NW/0030

• Date of REC Opinion

  18 Mar 2024

• REC opinion

  Further Information Favourable Opinion